Our work that inactivating GNA13 increases sensitivity of GCB-DLBCL cells to the BCL2 inhibitor may serve as a new therapeutic strategy for GCB-DLBCL. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.